Bright Minds Biosciences Inc. (DRUG)

NASDAQ: DRUG · Real-Time Price · USD

76.91

-1.13 (-1.45%)

Jan 2, 2026, 11:49 AM EST - Market open

Bright Minds Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2019 - 2020
Net Income	-12.23	-2.8	-7.37	-14.96	-8.65	Upgrade
Depreciation & Amortization	0.08	0.07	0.07	0.01	-	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	0	-	Upgrade
Stock-Based Compensation	3.18	0.84	1.15	0.9	0.88	Upgrade
Other Operating Activities	-0.28	-0	0.07	-0.26	0.14	Upgrade
Change in Accounts Payable	1.69	0.24	-1.2	0.77	0.51	Upgrade
Change in Other Net Operating Assets	-1.13	-0.2	0.26	-0.04	-0.2	Upgrade
Operating Cash Flow	-8.69	-1.85	-7.02	-13.59	-7.32	Upgrade
Long-Term Debt Repaid	-0.1	-0.09	-0.09	-0.01	-	Upgrade
Net Debt Issued (Repaid)	-0.1	-0.09	-0.09	-0.01	-	Upgrade
Issuance of Common Stock	86.03	0.9	1.47	6	27.84	Upgrade
Other Financing Activities	-0.36	-	0.8	-0.8	-1.79	Upgrade
Financing Cash Flow	85.57	0.81	2.19	5.2	26.06	Upgrade
Foreign Exchange Rate Adjustments	0.31	0.01	-0.05	0.26	0.22	Upgrade
Net Cash Flow	77.19	-1.03	-4.88	-8.13	18.96	Upgrade
Levered Free Cash Flow	-4.6	-0.69	-4.22	-7.58	-3.85	Upgrade
Unlevered Free Cash Flow	-4.58	-0.69	-4.22	-7.58	-3.85	Upgrade
Change in Working Capital	0.55	0.04	-0.94	0.72	0.31	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q